@article{Anthony R. Mato_Meghan Thompson_John N. Allan_Danielle M. Brander_John M. Pagel_Chaitra S. Ujjani_Brian T. Hill_Nicole Lamanna_Frederick Lansigan_Ryan Jacobs_Mazyar Shadman_Alan P. Skarbnik_Jeffrey J. Pu_Paul M. Barr_Alison R. Sehgal_Bruce D. Cheson_Clive S. Zent_Hande H. Tuncer_Stephen J. Schuster_Peter V. Pickens_Nirav N. Shah_Andre Goy_Allison M. Winter_Christine Garcia_Kaitlin Kennard_Krista Isaac_Colleen Dorsey_Lisa M. Gashonia_Arun K. Singavi_Lindsey E. Roeker_Andrew Zelenetz_Annalynn Williams_Christina Howlett_Hanna Weissbrot_Naveed Ali_Sirin Khajavian_Andrea Sitlinger_Eve Tranchito_Joanna Rhodes_Joshua Felsenfeld_Neil Bailey_Bhavisha Patel_Timothy F. Burns_Melissa Yacur_Mansi Malhotra_Jakub Svoboda_Richard R. Furman_Chadi Nabhan_2018, place={Pavia, Italy}, title={Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States}, volume={103}, url={https://haematologica.org/article/view/8590}, DOI={10.3324/haematol.2018.193615}, abstractNote={Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia treated with venetoclax to describe outcomes, toxicities, and treatment selection following venetoclax discontinuation. A total of 141 chronic lymphocytic leukemia patients were included (98% relapsed/refractory). Median age at venetoclax initiation was 67 years (range 37-91), median prior therapies was 3 (0-11), 81% unmutated <em>IGHV</em&gt;, 45% del(17p), and 26.8% complex karyotype (≥ 3 abnormalities). Prior to venetoclax initiation, 89% received a B-cell receptor antagonist. For tumor lysis syndrome prophylaxis, 93% received allopurinol, 92% normal saline, and 45% rasburicase. Dose escalation to the maximum recommended dose of 400 mg daily was achieved in 85% of patients. Adverse events of interest included neutropenia in 47.4%, thrombocytopenia in 36%, tumor lysis syndrome in 13.4%, neutropenic fever in 11.6%, and diarrhea in 7.3%. The overall response rate to venetoclax was 72% (19.4% complete remission). With a median follow up of 7 months, median progression free survival and overall survival for the entire cohort have not been reached. To date, 41 venetoclax treated patients have discontinued therapy and 24 have received a subsequent therapy, most commonly ibrutinib. In the largest clinical experience of venetoclax-treated chronic lymphocytic leukemia patients, the majority successfully completed and maintained a maximum recommended dose. Response rates and duration of response appear comparable to clinical trial data. Venetoclax was active in patients with mutations known to confer ibrutinib resistance. Optimal sequencing of newer chronic lymphocytic leukemia therapies requires further study.}, number={9}, journal={Haematologica}, author={Anthony R. Mato and Meghan Thompson and John N. Allan and Danielle M. Brander and John M. Pagel and Chaitra S. Ujjani and Brian T. Hill and Nicole Lamanna and Frederick Lansigan and Ryan Jacobs and Mazyar Shadman and Alan P. Skarbnik and Jeffrey J. Pu and Paul M. Barr and Alison R. Sehgal and Bruce D. Cheson and Clive S. Zent and Hande H. Tuncer and Stephen J. Schuster and Peter V. Pickens and Nirav N. Shah and Andre Goy and Allison M. Winter and Christine Garcia and Kaitlin Kennard and Krista Isaac and Colleen Dorsey and Lisa M. Gashonia and Arun K. Singavi and Lindsey E. Roeker and Andrew Zelenetz and Annalynn Williams and Christina Howlett and Hanna Weissbrot and Naveed Ali and Sirin Khajavian and Andrea Sitlinger and Eve Tranchito and Joanna Rhodes and Joshua Felsenfeld and Neil Bailey and Bhavisha Patel and Timothy F. Burns and Melissa Yacur and Mansi Malhotra and Jakub Svoboda and Richard R. Furman and Chadi Nabhan}, year={2018}, month={Aug.}, pages={1511-1517} }